U.S. Markets closed

Fresenius SE & Co. KGaA (FRE.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
21.95+0.73 (+3.44%)
At close: 05:35PM CEST

Fresenius SE & Co. KGaA

Else-Kroener-Strasse 1
Bad Homburg vor der Höhe 61352
49 6172 608 2487

IndustryMedical Care Facilities
Full Time Employees317,242

Key Executives

NameTitlePayExercisedYear Born
Mr. Stephan SturmCEO, Pres & Chairman of Management Board - Fresenius Management SE3.81MN/A1963
Ms. Rachel Clare EmpeyCFO & Member of Management Board - Fresenius Management SE2.14MN/A1976
Dr. Francesco De MeoMember of Management Board - Fresenius Management SE2.35MN/A1963
Dr. Ernst WastlerMember of Management Board - Fresenius Management SE1.8MN/A1958
Mr. Rice PowellMember of Management Board - Fresenius Management SE3.82MN/A1955
Dr. Sebastian BiedenkopfChief Legal Officer, HR, Labor Relations Director, Risk Mgmt & Member of Mgmt. Board1.51MN/A1964
Mr. Michael SenMember of Management Board - Fresenius Management SE2.23MN/A1968
Mr. Markus GeorgiSr. VP of Investor RelationsN/AN/AN/A
Matthias LinkSr. VP Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Corporate Governance

Fresenius SE & Co. KGaA’s ISS Governance QualityScore as of July 1, 2022 is 1. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.